ProHealth health Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help

|
|
|
|

Trending News

Vitamin D Deficiency Linked to Neurological Diseases; Also Raises Risk of Asthma Attacks, and More

Repair Damaged Mitochondria and Reduce Fatigue Up to 45%

7 Best Foods You Can Eat

Study: Doubling saturated fat in the diet does not increase saturated fat in blood

The Gut Microbiome and the Brain

Fight Inflammation and Promote Cognitive Health with High-OPC Grape Seed

CoQ10 supplementation reduces statin-related muscle pain in randomized trial

Controlling obesity with potato extract

Plant used in traditional Chinese medicine may treat metabolic diseases and obesity

Natural Gut Viruses Join Bacterial “Cousins” in Maintaining Health and Fighting Infections

 
Print Page
Email Article

Antidepressant Mirtazapine Studied for Fibromyalgia

  [ 1 vote ]   [ Discuss This Article ]
www.ProHealth.com • June 13, 2013


Editor's comment: Mirtazapine (brand name Remeron) is a tetracyclic antidepressant. It is not known exactly how mirtazapine works but it is thought to increase the activity of certain chemicals in the brain (eg, norepinephrine, serotonin).

Efficacy and Safety of Mirtazapine in Fibromyalgia Syndrome Patients: A Randomized Placebo-Controlled Pilot Study (July/August).

Abstract:

BACKGROUND:
Data from an open-label trial suggest that mirtazapine might prove useful in treatment of fibromyalgia syndrome (FMS).

OBJECTIVE:
To obtain preliminary efficacy data of mirtazapine for estimation of sample size requirements for a Phase 2 clinical trial in FMS.

METHODS: This 13-week randomized controlled trial compared the effects of mirtazapine 15 mg/day, mirtazapine 30 mg/day, and placebo in 40 patients with FMS. The primary outcomes were change in Pain Visual Analog Scale (PVAS) and proportion of pain responders (?30% PVAS reduction). Secondary outcomes included scores from the Jenkins Sleep Scale (JSS), Patient Global Impression of Change (PGIC), Fibromyalgia Impact Questionnaire (FIQ), Hamilton Depression Rating Scale (HAM-D), Patient Global Assessment, and self-reported adverse events.

RESULTS:

  • Significant within-group PVAS reductions from baseline were observed in all 3 groups, with the greatest improvement in the mirtazapine 30-mg group (p < 0.005); between-group difference was not significant.

  • The proportion of pain responders did not meet significance criteria (66.67% for mirtazapine 30 mg, 50% for mirtazapine 15 mg, 41.67% for placebo).

  • Significant within-group improvement in JSS scores was seen for mirtazapine 30 mg (p < 0.01) and mirtazapine 15 mg (p < 0.05).

  • Between-group comparison achieved significance for JSS item 3, waking several times per night (p < 0.05).

  • On the PGIC, 72.73% felt better with both mirtazapine dosages compared with 50% for placebo.

  • Within-group FIQ responses indicated improvement in only mirtazapine-treated groups, whereas within-group improvement for HAM-D and Patient Global Assessment was observed in all groups.

  • Based on our findings, the sample size requirement (80% power, 5% type I error) should be 83 per group to detect PVAS change difference between mirtazapine 30 mg and placebo.

Common mirtazapine-related adverse events were increased appetite and weight gain.

CONCLUSIONS:
Patients with FMS taking mirtazapine exhibited within-group significant improvement in most of the measured outcomes. Between-group analysis was predictably compromised by the small sample size. Mirtazapine was well tolerated. Further study with a larger sample size is likely to be useful.

Source:
The Annals of Pharmacotherapy, June 4, 2013. By Suwimon Yeephu, Chuthamanee Suthisisang, Saithip Suttiruksa, Pradit Prateepavanich, Patchara Limampai, and Irwin Jon Russell. Department of Pharmacology, Mahidol University, Rajthevee, Bangkok, Thailand.




Please Discuss This Article:   Post a Comment 



[ Be the first to comment on this article ]




 
Free Chronic Fatigue Syndrome and Fibromyalgia Newsletters
Subscribe to
Our FREE
Newsletter
Subscribe Now!
Receive up-to-date ME/CFS & Fibromyalgia treatment and research news
 Privacy Guaranteed  |  View Archives

Save on Nutritional Supplement Orders

Featured Products

Optimized Curcumin Longvida® by ProHealth Optimized Curcumin Longvida® by ProHealth
Supports Cognition, Memory & Overall Health
Energy NADH™ 12.5mg Energy NADH™ 12.5mg
Improve Energy & Cognitive Function
Vitamin D3 Extreme™ by ProHealth Vitamin D3 Extreme™ by ProHealth
50,000 IU Vitamin D3 - Prescription Strength
FibroSleep™ by ProHealth FibroSleep™ by ProHealth
The All-in-One Natural Sleep Aid
Ultra EPA  - Fish Oil Ultra EPA - Fish Oil
Ultra concentrated source of essential fish oils

Natural Remedies

Anti-Inflammatory Properties of Tart Cherry Anti-Inflammatory Properties of Tart Cherry
Research Links Green Tea to Weight Loss Research Links Green Tea to Weight Loss
Green Coffee Extract: Unique Obesity Intervention Green Coffee Extract: Unique Obesity Intervention
The Big Blue Fish that Helps Chase the Blues Away The Big Blue Fish that Helps Chase the Blues Away
The Curcumin Revolution: The Curcumin Revolution: "Golden" Ticket to Better Health

FIBROMYALGIA RESOURCES
What is Fibromyalgia?
Fibromyalgia Diagnosis
Fibromyalgia Symptoms
Fibromyalgia Treatments
| CFS RESOURCES
What is CFS?
ME/CFS Diagnosis
ME/CFS Symptoms
ME/CFS Treatments
| FORUMS
Fibromyalgia
ME/CFS
ADVANCED MEDICAL LABS
WHOLESALE  |  AFFILIATES
GUARANTEE  |  PRIVACY
CONTACT US
LIBRARY
RSS
SITE MAP
ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus
Credit Card Processing